Join the Oncology Voice Network. Join for Free
Why and How to Build a “Community” MSL Team
Community MSL teams KOL mapping community MSL roles engagement strategies MSL career advancement

Why and How to Build a “Community” MSL Team


Share This Article


Summary

In this episode, Bobby Faison joins to discuss the concept and implementation of community MSL teams. The conversation highlights the importance of building these teams, their roles in KOL mapping, and effective engagement strategies. Bobby covers essential aspects such as hiring, qualifications, and entry-level opportunities for community MSLs, alongside the challenges they face. The episode delves into the dynamics between community MSLs and commercial teams, territory management, and travel considerations. Bobby also examines the metrics for assessing the community MSL model's success and offers career advancement advice. The episode concludes with insights into customer segmentation and its impact on field medical teams.

My guest today is Bobby Faison, Executive Director, Medical Affairs with Paratek Pharmaceuticals. Bobby discusses why and how to build a “Community” MSL team.

Bobby shares…

👉 What is a “Community” MSL
👉 How a “Community” MSL is different from a traditional, therapeutic MSL
👉 What the relationship with commercial looks like
👉 What the expectations are for “Community” MSLs in regard to metrics and KPIs
👉 Advice for organizations looking to implement this model
👉 Why the Community MSL role is a great pathway for Aspiring MSLs

Click for Source
Community MSL teams, KOL mapping, community MSL roles, engagement strategies, MSL career advancement

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
KPIs: Why Quantitative WON’T Work Without Qualitative Outcomes
Partner Avatar MSL Talk: Tom Caravela, Linda Traylor, Rena Patel

KPIs: Why Quantitative WON’T Work Without Qualitative Outcomes

Podcast
Digital Opinion Leaders: What You Should Know About DOLs
Partner Avatar MSL Talk: Tom Caravela, Omar McMillan

Digital Opinion Leaders: What You Should Know About DOLs

Article
The Oncology Data Network (ODN): Methodology, Challenges, and Achievements
OVN Avatar Ashley Woolmore , Dirk Arnold , Jean‐Yves Blay , Christian Buske , Alfredo Carrato , Winald Gerritsen , Marc Peeters , Jesus Garcia‐Foncillas , David Kerr

The Oncology Data Network (ODN): Methodology, Challenges, and Achievements

Article
Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs
OVN Avatar Alyson Haslam, PhD; Vinay Prasad, MD, MPH

Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs

Article
Loose Regulatory Standards Portend a New Era of Imprecision Oncology
OVN Avatar Ali Raza Khaki

Loose Regulatory Standards Portend a New Era of Imprecision Oncology

Article
Expert perspectives live from ASCO® 2025
Partner Avatar iNIZIO

Expert perspectives live from ASCO® 2025

Explore OVN